Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date

Alberto Gajofatto
Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy

Abstract: Siponimod (BAF312) is a synthetic molecule belonging to the sphingosine-1-phosphate (S1P) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of B and T cells in secondary lymphoid organs. Compared to fingolimod (ie, precursor of the S1P modulators commercially available for the treatment of relapsing–remitting [RR] multiple sclerosis [MS]), siponimod exhibits selective affinity for types 1 and 5 S1P receptor, leading to a lower risk of adverse events that are mainly induced by S1P3 receptor activation, such as bradycardia and vasoconstriction. In addition, S1P1 and S1P5 receptors are expressed by neurons and glia and could mediate a possible neuroprotective effect of the drug. A Phase II clinical trial of siponimod for RR MS showed a significant effect of the active drug compared to placebo on reducing gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) after 3 months of treatment. In a recently completed Phase III trial, treatment with siponimod was associated with a significant reduction in disability progression in secondary progressive (SP) MS patients compared to placebo. In this article, current evidence supporting siponimod efficacy for SP MS is reviewed.

Keywords: multiple sclerosis, siponimod, progression, disability, treatment

Background

Secondary progressive (SP) multiple sclerosis (MS) is a clinical subtype of the disease characterized by continuous worsening of neurological disability that begins insidiously in patients with a preceding relapsing–remitting (RR) course, which is the mode of onset of ~90% of cases. The risk and timing of transition from RR MS to SP MS are highly unpredictable in the individual MS patient; however, it is estimated that up to 90% of RR MS cases may evolve to SP MS over a 25-year time interval. While patients with RR MS tend to recover fully or partially after relapses and may experience mild neurological symptoms, SP MS cases usually have gradual – although not necessarily steady – accumulation of neurological disability, typically affecting walking, sphincter control, hand function, speech, swallowing, and cognition. In addition, several disease-modifying therapies (DMTs) have shown efficacy in reducing relapses and overall disease activity in RR MS, while the majority of these and other investigational treatments have failed to prevent disease worsening in progressive MS. This may be explained by the predominance of acute inflammation, which is the main biological target of available MS DMTs, in the pathophysiology of RR MS clinical manifestations, ie, relapses that are known to decrease in frequency or even cease after the transition to an SP course. However, in the pathological continuum

Correspondence: Alberto Gajofatto
Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Piazzale LA Scuro 9, 37134 Verona, Italy
Tel +39 45 812 4768
Fax +39 45 802 7492
Email alberto.gajofatto@univr.it
between RR MS and SP MS, other factors may play a role, such as the effect of longstanding inflammation; exhaustion of compensatory and reparative mechanisms; and genetic, age-dependent, and exogenous factors.\textsuperscript{3} Approved DMTs for MS have little or no effect on the regulation of these biological processes as demonstrated by the modest or absent benefit of most treatments on disability progression that is independent of relapses.

Recently, a large Phase III placebo-controlled trial of the investigational agent siponimod for SP MS met its primary efficacy end point, showing a statistically significant reduction in confirmed disability progression in patients receiving the experimental intervention.\textsuperscript{4} The present article reviews the characteristics and development of siponimod and discusses its potential for future clinical use in MS.

**“Discovery” of BAF312 (siponimod)**

Siponimod (BAF312) is a structural analog of sphingosine, which is an endogenous sphingolipid involved in the regulation of a variety of biological functions, including lymphocyte trafficking, cardiomyocyte function, vascular development, and cell survival.\textsuperscript{5} Sphingosine-1-phosphate (S1P) is the bioactive metabolite of sphingosine in vivo, which binds to a family of G-protein-coupled receptors consisting of five distinct subtypes (S1PR1–S1PR5) expressed differentially on the surface of several cell types, eg, myocytes (S1PR1 and S1PR3), lymphocytes (S1PR1), astrocytes, oligodendrocytes, and neurons (S1PR1 and S1PR5). Of importance for immune system regulation, interaction of S1P with S1PR1 is essential for the egression of a subset of lymphocytes from secondary lymphoid organs and their redistribution to other tissues. The discovery that a chemically modified natural sphingolipid (ie, fingolimod) exhibits immunosuppressive effects after in vivo phosphorylation, by functionally antagonizing S1PR1 and thus sequestrating B and T cells in lymphoid tissues, led to the clinical development and approval of this molecule for the treatment of RR MS.\textsuperscript{6} However, fingolimod also has affinity for other S1PR subtypes, including S1PR3 that is internalized by cardiac myocytes after interaction with the phosphorylated form of the drug, leading to heart rate reduction, and rarely to atrioventricular block and cardiac arrest, particularly in the first 24 hours after treatment start. It is therefore recommended to perform 6-hour cardiac monitoring in all patients initiating fingolimod. In addition, fingolimod has a prolonged half-life in human beings requiring ~2 months for elimination after treatment interruption. These limitations prompted the pharmaceutical industry to develop S1PR modulators with shorter half-life and lacking affinity for S1PR3 with the objective of combining fingolimod efficacy for MS with a better pharmacokinetic and safety profile.

Siponimod is a synthetic derivative of fingolimod obtained with modifications providing increased rigidity in the lipophilic alkyl chain, which confers selectivity for S1PR1 and SIPR5 as shown in vitro.\textsuperscript{7} In vivo preclinical studies showed that siponimod was safe and significantly ameliorated symptoms of the murine animal model of MS (ie, experimental autoimmune encephalitis [EAE]),\textsuperscript{8} opening the way to the development of clinical trials of BAF312 for patients with MS.

**Siponimod clinical development for MS**

An exploratory Phase I trial of siponimod showed that drug administration was overall safe at multiple doses in a group of 48 healthy volunteers, although it induced transient (day 1 only) bradycardia despite sparing of S1PR3. In fact, BAF312 activates GIRQK channels in human atrial myocytes likely through interaction with S1PR1, causing bradycardia.\textsuperscript{8} Pharmacokinetic analysis revealed that siponimod half-life is 30 hours with complete drug elimination in ~7 days. Following these findings, a dose-ranging randomized Phase II trial assessed the safety and efficacy of BAF312 vs placebo (BOLD study) in two independent cohorts of patients with RR MS enrolled in 72 centers.\textsuperscript{9} Subjects in cohort 1 (N=188) received once daily siponimod 10 mg, 2 mg, 0.5 mg, or placebo (1:1:1:1) for 6 months. After a 3-month interim analysis, 109 additional patients were allocated to once daily siponimod 1.25 mg, 0.25 mg, or placebo (4:4:1) for 3 months (cohort 2). Patients in cohort 1 immediately received the full siponimod dose, while in cohort 2, a masked titration scheme was implemented for treatment initiation. The primary outcome was the dose–response relationship of the five doses of siponimod compared with placebo during 3 months of treatment, based on the number of new gadolinium-enhancing lesions on T1-weighted images and new or newly enlarged non-enhancing lesions on T2-weighted monthly brain magnetic resonance imaging (MRI) scans. Secondary end points included also clinical efficacy measures, such as annualized relapse rate and proportion of relapse-free patients, and safety/tolerability data. Siponimod doses of 10, 2, 1.25, and 0.5 mg significantly reduced the number of new brain lesions (as defined in the primary end point) at 3 months compared to placebo with a dose-dependent relation. In addition, siponimod 2 mg significantly reduced the annualized relapse rate at 6 months compared to placebo.
A dose-dependent decrease in heart rate was observed during treatment initiation on day 1, reaching nadir at ~3 hours after dosing and returning to levels similar to placebo in the following 24 hours in all treatment groups. Dose titration (siponimod 1.25 mg group) mitigated heart rate reduction compared to full-dose administration on day 1. First- and second-degree atrioventricular blocks were reported in nine patients receiving siponimod 10, 2, or 0.5 mg. As expected, there was a dose-dependent total lymphocyte count decrease by 20%–74% at day 7 of siponimod treatment compared to baseline, which remained stable up to 3 and 6 months. Increased alanine aminotransferase concentrations were reported more frequently in the siponimod groups compared to placebo. In the 24-month extension of the trial, patients receiving siponimod continued with the originally allocated dose, while patients on placebo were randomized at baseline to one of the five siponimod doses. The incidence of adverse events was similar across treatment groups. Nine out of 252 enrolled patients had serious adverse events, but no new or unexpected safety concerns emerged compared to the core BOLD study. The number of gadolinium-enhancing T1 lesions and new T2 lesions on brain MRI and the annualized relapse rates remained low over 24 months, particularly with the three or four highest siponimod doses.

In 2012, a large randomized, placebo-controlled, double-blind Phase III trial of siponimod for SP MS (EXPAND study) was started in 31 countries. Eligible patients were aged 18–60 years, had progressive increase in disability for at least 6 months in the absence or independent of relapses, and a baseline Expanded Disability Status Scale (EDSS) score from 3.0 to 6.5. The primary efficacy outcome was time to 3-month confirmed disability progression measured by EDSS. The key secondary outcomes were time to confirmed worsening of ≥20% from baseline in the timed 25-foot walk test and brain T2 lesion volume change from baseline. The study enrolled 1,651 patients (60% women) who were randomized 2:1 to receive either siponimod 2 mg daily (with initial 6-day dose titration starting at 0.25 mg) or placebo for a variable duration determined by the time at which a prespecified number of patients reached the primary outcome in the overall study population. At baseline, mean age was 48 years, median EDSS score was 6.0, and 75% of patients had no gadolinium-enhancing T1 lesions. In addition, relapses in the 2 years prior to study start were documented in 35% of patients. Of the 1,651 included patients, 1,363 (83%) completed the study. Median time on study was 21 months, with the majority of patients (87%) participating for at least 1 year. Overall, there were 449 confirmed disability progression events. Treatment with siponimod was associated with 21% reduction in the risk of disability progression confirmed at 3 months (26%/6 months) compared to placebo (hazard ratio = 0.79, p = 0.013 and hazard ratio = 0.74, p = 0.006, respectively).

Accordingly, siponimod treatment showed a beneficial effect on other secondary efficacy outcomes, including the annualized relapse rate, T2 lesion volume, new T2 lesions, and number of gadolinium-enhancing lesions (p < 0.0001 for all comparisons vs placebo). In addition, a benefit on percent brain volume change was also reported in patients receiving siponimod (p = 0.0002 vs placebo). Siponimod did not show a significant benefit on ambulation impairment as measured by timed 25-foot walk. Adverse events in the siponimod group occurred at a similar rate (88.7%), to that observed in the previous BOLD RR MS trial, leading to treatment discontinuation in 7.6% of patients. Most common adverse events (>10%) were headache, nasopharyngitis, urinary tract infection, falls, and hypertension. Serious adverse events occurred in 17.9% of patients on siponimod and 15.2% of patients receiving placebo. Incidence of deaths (0.4% vs 0.7%), malignancies (1.9% vs 2.6%), and infections (49.0% vs 49.1%) was similar between treatment groups. Adverse events of interest included bradyarrhythmias (3.5% vs 2.4%), hypertension (12.6% vs 9.3%), and macular edema (1.8% vs 0.2%). Lymphopenia <2.0×10^9/μL was observed in 2.7% vs 0.2% of patients, and liver function test elevation was three or more times greater than upper normal limit in 5.6% vs 1.5% of patients.

**Discussion – insights into potential siponimod efficacy for SP MS**

SP MS is characterized by irreversible accrual of disability over time as a consequence of insidious worsening of neurological symptoms rather than failure of relapse recovery. This type of MS course is lacking a substantially effective treatment to reduce disability progression independent of relapses. The results reported for the siponimod Phase III SP MS study (ie, the largest clinical trial for SP MS ever) are encouraging, although the final data have still to be published in a full peer-reviewed paper. Based on available information, siponimod showed a statistically significant effect on reducing confirmed EDSS progression over ~2 years of treatment on average compared to placebo. This finding was consistent with the reduction in the relapse rate during the trial and the effect favoring siponimod on several MRI measures, including brain atrophy, new/enlarging T2 lesions, and gadolinium-enhancing lesions. However, there was a discrepancy with the...
data observed for a key secondary clinical end point, ie, gait speed measured by timed 25-foot walk, on which treatment with siponimod did not show a significant benefit. Although the full data analysis is not published yet, the magnitude of siponimod effect on the primary end point of the EXPAND trial (ie, 21% reduction of 3-month confirmed EDSS score progression compared to placebo) appears robust and suggests a possible clinically meaningful benefit of the drug, particularly because of the scarcity of effective therapies for SP MS patients.

Currently approved DMTs for SP MS include interferon-beta-1b and mitoxantrone, based on the results of two clinical trials that showed some benefits of these drugs on disability progression compared to placebo. In the trial conducted by the European Study Group on interferon beta-1b in SP MS, patients treated with interferon showed significantly less EDSS progression that was confirmed at 3 months compared to patients receiving placebo over 3 years (39% vs 50%).

In the trial of mitoxantrone for rapidly progressive MS, patients on active drug had a stable or improved EDSS score at 2 years in a significantly higher proportion than patients treated with placebo (mean EDSS change −0.13 vs +0.23). Both studies recruited an “active” SP MS population, characterized by a high pretrial relapse rate and/or presence of gadolinium-enhancing lesions on baseline brain MRI. Post hoc analyses demonstrated that most of the effects on disability progression observed with interferon beta and mitoxantrone were actually driven by the significant relapse rate reduction determined by the active drugs rather than by halting disability progression per se. In fact, other trials of interferon beta-1a and -1b enrolling SP MS patients with lower prestudy relapse rate failed to show a significant benefit on EDSS progression. Similarly, several additional clinical trials were not able to consistently show a significant benefit of immunomodulatory and immunosuppressive drugs on disability progression in SP MS patients, with few exceptions.

Among therapies not directly targeting the immune system, the potential neuroprotective effect of siponimod suggested by these studies could explain the benefit observed on disability progression in patients with SP MS treated with this drug.

In contrast with these findings, the INFORMS trial failed to show a significant effect of fingolimod vs placebo on 3-month confirmed disease progression (measured on a composite end point including EDSS score, 9-hole peg test, and timed 25-foot walk test) in a large population (n=970) of PP MS patients followed for at least 3 years. Besides the different primary end points of the EXPAND and INFORMS trials, other factors may explain the divergent findings of the two studies. The EXPAND trial had an adaptive design in
terms of duration, since the trial was stopped when a predetermined number of events were reached. This methodological strategy might have enhanced the likelihood of detecting an effect of treatment compared to the PP MS fingolimod trial. Other possible explanations of the success of the siponimod trial as opposed to the failure of the fingolimod one in progressive MS are the intrinsic pathogenetic differences between SP and PP MS and the selective interaction of siponimod with types 1 and 5 S1PR, which are known to mediate protective effects on oligodendrocytes, microglia, astrocytes, and neurons. Overall, S1PR modulators family seems to represent a promising treatment strategy for MS as indicated by the recent findings of ponesimod, ozanimod, and amiselimod Phase II trials in relapsing MS. Publication of final data of the EXPAND trial and further research to confirm the promising results of siponimod and other S1PR modulators studies in MS are warranted.

Disclosure
The author reports no conflicts of interest in this work.

References